Liumbruno et al., 2015 - Google Patents
Solvent/detergent-treated plasma: a tale of 30 years of experienceLiumbruno et al., 2015
- Document ID
- 7821423959820534497
- Author
- Liumbruno G
- Marano G
- Grazzini G
- Capuzzo E
- Franchini M
- Publication year
- Publication venue
- Expert review of hematology
External Links
Snippet
Solvent/detergent-treated plasma was licensed> 30 years ago. It has several specific characteristics, the most important being the standardized content of clotting factors, the lack of antibodies implicated in transfusion-related acute lung injury pathogenesis and the very …
- 210000002381 Plasma 0 title abstract description 224
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bux et al. | Quality of freeze‐dried (lyophilized) quarantined single‐donor plasma | |
| British Committee for Standards in Haematology, Blood Transfusion Task Force (J. Duguid, Chairman) et al. | Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant | |
| Jensen et al. | Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review | |
| Liumbruno et al. | Solvent/detergent-treated plasma: a tale of 30 years of experience | |
| Jenkins et al. | Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps | |
| Goldstein et al. | Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial | |
| Hellstern et al. | The use of solvent/detergent treatment in pathogen reduction of plasma | |
| Benjamin et al. | Plasma components: properties, differences, and uses | |
| Saadah et al. | Comparing transfusion reaction rates for various plasma types: a systematic review and meta‐analysis/regression | |
| Hellstern | Solvent/detergent-treated plasma: composition, efficacy, and safety | |
| Thibault et al. | Characterization of blood components prepared from whole‐blood donations after a 24‐hour hold with the platelet‐rich plasma method | |
| De Alarcon et al. | Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies | |
| Toussaint‐Hacquard et al. | Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study | |
| Liumbruno et al. | Solvent/detergent plasma: pharmaceutical characteristics and clinical experience | |
| Levy et al. | Therapeutic plasma transfusion in bleeding patients: a systematic review | |
| El‐Ekiaby et al. | Solvent‐detergent filtered (S/D‐F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system | |
| Greening et al. | International blood collection and storage: clinical use of blood products | |
| Prowse | Properties of pathogen-inactivated plasma components | |
| Kasper | Judith Graham Pool and the discovery of cryoprecipitate. | |
| Boehme et al. | Anticoagulation control in patients with ventricular assist devices | |
| Lozano et al. | Pathogen inactivation: coming of age | |
| Atreya et al. | Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) | |
| Jenkins et al. | THOR position paper on remote damage control resuscitation: definitions, current practice and knowledge gaps | |
| Lokhandwala et al. | Hemostatic profile and safety of pooled cryoprecipitate up to 120 hours after thawing | |
| Jilma‐Stohlawetz et al. | Recovery, safety, and tolerability of a solvent/detergent‐treated and prion‐safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers |